数据显示，中国富达基金旗下1只基金重仓中国神华。富达悦享红利优选混合A（020493）二季度持有 股数22.6万股，占基金净值比例为4.14%，位居第九大重仓股。根据测算，今日浮盈赚取约4.75万元。 连续6天上涨期间浮盈赚取56.73万元。 10月15日，中国神华涨0.52%，截至发稿，报40.86元/股，成交15.45亿元，换手率0.23%，总市值 8118.28亿元。中国神华股价已经连续6天上涨，区间累计涨幅6.54%。 资料显示，中国神华能源股份有限公司位于北京市东城区安定门西滨河路22号,香港中环花园道1号中银 大厦60楼B室，成立日期2004年11月8日，上市日期2007年10月9日，公司主营业务涉及煤炭和电力的生 产与销售、铁路和港口运输,航运业务,煤制烯烃业务。主营业务收入构成为：煤炭75.23%，发电 29.35%，铁路15.52%，港口2.51%，煤化工2.11%，航运1.19%，未分配项目0.31%。 从基金十大重仓股角度 截至发稿，聂毅翔累计任职时间8年76天，现任基金资产总规模3.07亿元，任职期间最佳基金回报 135.58%， 任职期间最差基金回报-18.79%。 周文群累计任职时 ...

Core Viewpoint - The AI Fund Fidelity Enjoy Dividend Preferred Mixed A (020493) reported a profit of 7.5547 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.0873 yuan, and a net asset value growth rate of 10.19% during the same period [2]. Fund Performance - As of September 3, the fund's net asset value growth rate over the past three months was 16.30%, ranking 384 out of 607 comparable funds; over the past six months, it was 22.44%, ranking 237 out of 607; and over the past year, it was 25.69%, ranking 500 out of 604 [4]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 7.05 times, compared to the industry average of 33.74 times; the weighted average price-to-book (P/B) ratio was about 0.5 times, against an industry average of 2.47 times; and the weighted average price-to-sales (P/S) ratio was around 0.98 times, while the industry average was 2.07 times, indicating that all three valuation metrics are below the industry average [9]. Growth Metrics - For the first half of 2025, the weighted average year-on-year revenue growth rate (TTM) of the stocks held by the fund was 0.05%, and the weighted average net profit growth rate (TTM) was 0.03%, with a weighted annualized return on equity of 0.07% [15]. Fund Size and Shareholder Composition - As of June 30, 2025, the fund's total size was 49.2887 million yuan, with 839 holders collectively owning 46.5021 million shares. Management employees held 531,100 shares, accounting for 1.14%, while individual investors held 100% of the shares [31][34]. Trading Activity - The fund's turnover rate over the last six months was approximately 140.96%, which is consistently lower than the industry average [37].

Core Insights - Foreign public funds have shown strong performance in Q2, with a focus on structural opportunities in the Chinese market, particularly in artificial intelligence, innovative pharmaceuticals, and high-dividend assets [1][2][3] Group 1: Fund Performance - Several foreign public equity products achieved notable returns in Q2, with the Robeco China Healthcare Equity Fund leading at a 28.51% increase in net value [1] - BlackRock's Advanced Manufacturing Fund and Fidelity's Dividend Growth Fund reported net value increases of 21.83% and 13.64%, respectively [1] Group 2: Investment Strategies - Robeco emphasized a multi-dimensional evaluation of companies in the innovative sector, focusing on quality, talent, R&D investment, and clinical data to select high-potential firms [1] - BlackRock's fund manager highlighted a strategic focus on artificial intelligence and technology sectors, achieving significant excess returns [2] - Fidelity's managers noted strong performance in traditional dividend sectors, attracting risk-averse capital due to low valuations and high dividend certainty [2] Group 3: Future Outlook - Fund managers expressed optimism about the attractiveness of A-share valuations, supported by policy backing and positive industry trends, indicating ongoing structural opportunities [2] - Future investment will continue to prioritize high-quality technology assets and sectors with concentrated distribution, such as TMT, machinery, pharmaceuticals, and chemicals [3] - The Chinese pharmaceutical industry is expected to enhance its global competitiveness, with a clear trend towards international expansion in innovative drugs and medical devices [3]